Beginning in 2011, Springer will publish Neurotherapeutics, the official Journal of the American Society for Experimental NeuroTherapeutics (ASENT). With the switch to Springer, Neurotherapeutics will change its format of publishing review articles only to offering original research articles as well. The journal achieved a debut Impact Factor of 5.38 in 2009, placing it in the top quartile of journals in both the Neurosciences and Pharmacology & Pharmacy categories.
Throughout its six-year history, Neurotherapeutics has exclusively published critical reviews in thematic, quarterly issues that highlight neurotherapeutics related to the clinical neurosciences. Each issue is developed by one or more distinguished guest editors who are expert in the topic area. The journal's editor-in-chief is Dr. Alan Faden, who directs the Shock Trauma and Anesthesiology Research (STAR) Center at the University of Maryland School of Medicine.
Springer will create a Neurotherapeutics portal and a page on the NeuroNetwork to promote themed issues, facilitate communication among the journal's readers, promote society news, and highlight both the preclinical and clinical articles in the journal through RSS feeds and podcasts.
Dr. Matthew Giampoala, Publishing Editor of Biomedicine at Springer, said, "We are very excited to be working with ASENT on this unique journal. No other journal is so thoughtfully bridging the gap between basic neuroscience and effective therapeutic breakthroughs. Springer and ASENT will work together to help the journal reach the widest possible audience."
Dr. Faden is enthusiastic about the plan to include high quality primary research articles as well as targeted thematic reviews, and the move to Springer. "The field of neurotherapeutics has progressed rapidly in recent years and there is a need for a journal that can showcase research breakthroughs in this area. We look forward to the new partnership with Springer, with the expectation that it will help to promote the visibility and accessibility of our journal."
All back issues will be available on Springer's online platform SpringerLink. Neurotherapeutics will take advantage of the online submission system Editorial Manager and all articles will publish in the Online First format on SpringerLink ahead of print publication. In addition, all content from the journal will be provided to PubMed Central and available to the public twelve months after print publication.
The American Society for Experimental NeuroTherapeutics (http://www.asent.org) provides a forum for representatives from academia, government, advocacy groups, and industry focused on developing improved therapies for neurological disorders. The society also organizes education and training for healthcare practitioners, biomedical scientists and officials participating in the neurotherapeutics field.
Springer (http://www.springer.com) is a leading global scientific publisher of books and journals, delivering quality content through innovative information products and services. It publishes close to 500 academic and professional society journals. Springer is part of the publishing group Springer Science+Business Media. In the science, technology and medicine (STM) sector, the group publishes around 2,000 journals and more than 6,500 new books a year, as well as the largest STM eBook Collection worldwide. Springer has operations in about 20 countries in Europe, the USA, and Asia, and more than 5,000 employees.
ISSN: 1933-7213 (print version), ISSN: 1878-7479 (electronic version)
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.